Research by the DNA Damage & Disease research group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.
Researchers in Oxford have found that an individual\u2019s immune system \u2013 and in particular the presence of T-cells amongst tumour cells - may play an important role in survival after surgery to remove pancreatic cancer.
The Department of Oncology is pleased to announce that Professor Amato J Giaccia has been appointed as the new Director of the MRC Oxford Institute for Radiation Oncology (OIRO).
Researchers in the Department of Oncology have secured funding to characterise an insulin-like growth factor (IGF) signature for early detection and risk reduction of cancer.
Scientists from the Department of Oncology have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.
Greg Clark, UK Secretary of State for Business, Energy and Industrial Strategy (BEIS), will confirm today (Tuesday 6 November) that UK Research and Innovation will invest \u00a310million in the National Consortium of Intelligent Medical Imaging (NCIMI), to be led from Oxford University as part of the Industrial Strategy Challenge Fund.
Congratulations to Dr Xiao Wan from Professor Eric O\u2019Neill\u2019s group for her success in obtaining an NC3Rs Training Fellowship for \u2018Developing human organotypic perfused bioreactors for physiologically reproducible therapeutic compound screening of a tumour microenvironment\u2019.
Congratulations to Dr Bart Cornelissen of the CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology who has secured a \u00a3200k grant from UK medical research charity, Pancreatic Cancer Research Fund (PCRF).
Dr James Larkin, a postdoctoral researcher from Nicola Sibson\u2019s lab in the CRUK/MRC Oxford Institute for Radiation Biology, has won a silver medal in 2018 STEM for Britain, a Parliamentary poster competition that gives researchers the chance to present their work to policymakers and politicians and discuss their work with local MPs.
Many congratulations to Robert Watson, a NIHR Academic Clinical Fellow in the laboratory of Benjamin Fairfax in the Department of Oncology. Robert was successful in his application for a CRUK pre-doctoral research bursary.
Congratulations to Associate Professor Francesca Buffa who has been awarded a five-year \u20ac2M grant by the European Research Council (ERC) to develop computer simulations of cancer cell behaviour, to help us personalise cancer treatment and prevent drug resistance.
This month the MRC Weatherall Institute of Molecular Medicine (WIMM) hosted the annual Regional Breast Cancer Academic Day, an event that brings together breast cancer teams from across the Thames Valley region. This year\u2019s symposium involved the participation of over 70 attendees, including nurses, clinical trial managers, researchers and doctors.
Professor Nicola Sibson of the Department of Oncology has been awarded a grant worth almost \u00a3200,000 by research charity Breast Cancer Now to fund cutting-edge research to uncover novel treatment combinations to control breast cancer that has spread to the brain.
Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.
The development of new treatments for pancreatic cancer is set to be transformed by a network of pancreatic clinical trials, aiming to find the right trial for the right patient, after a \u00a310 million investment from Cancer Research UK announced today.
![](\"https://www.oncology.ox.ac.uk/news/sprtn-protease-and-checkpoint-kinase-1-cross-activation-loop-safeguards-dna-replication/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n